Clicky

Hutchison China MediTech Limited(HCM)

Description: Hutchison China MediTech Limited engages in the research, development, manufacture, and sale of pharmaceuticals and health oriented consumer products primarily in the People's Republic of China. It operates through three segments: China Healthcare, Drug Research and Development, and Consumer Products. The company manufactures, distributes, and sells over-the-counter, prescription, and health supplements products under the Bai Yun Shan and Shang Yao brands; and offers drug research and development services. It also offers traditional Chinese medicine products in cardiovascular and cold/flu therapeutic areas. In addition, the company develops clinical drug candidates, including HMPL-004 that is in Phase III clinical trials for ulcerative colitis and Crohn's disease; Fruquintinib, which is in Phase III clinical trial for the treatment of colorectal, non-small cell lung, and gastric cancer; and Sulfatinib, a Phase 1b clinical trial product for neuroendocrine tumours, as well as Epitinib for treating non-small cell lung cancer. Further, it offers Theliatinib, a Phase I clinical trial product for the treatment of solid tumours; AZD6094 that is in Phase 1b clinical trial for treating non-small cell lung and gastric cancer; HMPL-523 and HMPL-689, which are preclinical stage products for the treatment of hematological cancers; and HMPL-453 that is in preclinical stage for the treatment of solid tumours. The company also offers organic and natural food, beverage, baby, and beauty care products; and distributes organic and natural products. Hutchison China MediTech Limited has strategic collaborations with multinational pharmaceutical and healthcare companies, including AstraZeneca AB (Publ); Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; and Nestlé Health Science SA. The company was founded in 2000 and is based in Hong Kong, Hong Kong. Hutchison China MediTech Limited operates as a subsidiary of Hutchison Healthcare Holdings Limited.


Keywords: Pharmaceutical Beverage Drug Discovery Clinical Trial Non Small Cell Lung Cancer Traditional Chinese Medicine Small Cell Lung Cancer Ulcer Ulcerative Colitis Crohn's Disease Colitis Beauty Care Products Gastric Cancer Product Testing Natural Products Medicine Products Clinical Trial Product Hematological Cancers Natural Food Preclinical Stage Product Preclinical Stage Products Stage Products Treatment Of Hematological Cancers Hmpl 523 Nursing Research Organic And Natural Food Organic And Natural Products Solid Tumours

Home Page: www.hutch-med.com

HCM Technical Analysis

Cheung Kong Center
Central,
Hong Kong
Phone: 852 2128 1188


Officers

Name Title
Mr. Chi Keung To ACGI, B.Sc., BSc, M.B.A., MBA Exec. Chairman
Dr. Weiguo Su B.Sc., Ph.D. CEO, Chief Scientific Officer & Exec. Director
Mr. Chig Fung Cheng BEc, CA CFO & Exec. Director
Ms. Edith Shih C.S., CGP, FCS, M.A., P.E., BSE, EdM, Solicito Company Sec. & Non-Exec. Director
Dr. Karen Jane Atkin Exec. VP & COO
Mr. Kin Hung Lee M.B.A. Sr. VP of Corp. Fin. & Devel.
Mr. Charles George Rupert Nixon Group Gen. Counsel
Ms. Selina Zhang Sr. VP of Global HR
Dr. Qingmei Wang Ph.D. Sr. VP of Bus. Devel. & Strategic Alliances
Mr. Hong Chen Sr. VP & Chief Commercial Officer- China

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 3.0277
Price-to-Sales TTM: 5.9678
IPO Date: 2016-03-17
Fiscal Year End: December
Full Time Employees: 2110
Back to stocks